Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-21

Study Completion Date

2021-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

The ketogenic diet uses fats as a person's major energy source rather than carbohydrates. There is increasing interest in using this diet to treat neurodegenerative disorders like Parkinson's disease. Researchers want to learn more about the ketogenic diet before recommending this diet in clinical practice.

Objective:

To study the effects of a ketogenic diet for someone with PD.

Eligibility:

People over age 50 with mild to moderate PD.

Design:

Participants will be screened with surveys and a 10-foot walking test. They will have a medical history, physical exam, and blood test.

Participants will be contacted twice in a 1-week period to discuss what they ate over the last 24 hours. They will log data about their daily exercise and activities using an online fitness tracking app.

Participants will stay at NIH Clinical Center for 1 week. They will be put into 1 of 2 groups. One group will follow a ketogenic diet and take MCT oil. The other group will follow a low-fat diet. Their body measurements will be taken. They will meet with a physical therapist and nutritionist.

Participants will have daily respiratory and glucose monitoring. They will have cognitive tests and complete surveys. They will have walking, motor function, and reaction time/finger tapping tests. They will have heart and nerve function tests. They will have electrocardiograms and electroencephalograms. Blood will be taken twice daily.

Participants will follow the ketogenic diet at home for 2 weeks. They will log their activities using the fitness tracking app. Then they will have a follow-up visit at NIH.

Participation in the trial will last for 4 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome

NCT05469997

Parkinson Disease

ACTIVE_NOT_RECRUITING NA

Effect of a Lipidic and Proteic Controlled Diet on Parkinson's Disease

NCT02687698

Parkinson Disease

UNKNOWN NA

Ketogenic Diets for Symptoms of Parkinson's Disease

NCT01364545

Parkinson's Disease

UNKNOWN NA

Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease

NCT05998772

Parkinson Disease Nutritional and Metabolic Diseases Sugar Intake

RECRUITING

Microbiome and Diet in Parkinson's Disease

NCT06207136

Parkinson Disease Diet, Healthy Gut Microbiome +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description:

While three pilot studies of ketogenic diet (KD) in PD have shown either reduction in motor scores (UPDRS) or improved cognition (memory/fluency), there are gaps in knowledge of the time course and mechanisms of reported outcomes. Furthermore, only a standard ketogenic diet was studied while there are variations such as MCT oil supplementation shown to increase keto-induction, and other adaptations may improve tolerability and micronutrient content. It is the goal of this proposed inpatient metabolic study to address the initial question of effect size and time course of ketosis. If suggestive of benefit in PD, this pilot study may lead to a subsequent larger study of long-term feasibility and effects on disease biomarkers and disease progression, which might also compare alternate diets of interest in PD such as Mediterranean diet. Thus, a pilot feasibility study is proposed, targeting retention rate \>80% and adherence in the outpatient setting. Recruitment of 32 participants is based upon power analysis of secondary outcome, testing the Timed Up \& Go mobility test that has reported validity in fall prediction, additionally plotting continuous and serially repeated direct/indirect ketosis measurements and motor as well as non-motor symptoms / exploratory disease biomarkers. It is hypothesized that, compared to a non-ketogenic, standard American diet (SAD, also referred to interchangeably as usual diet, ketogenic diet supplemented by MCT oil (MCT-KD) will improve mobility tested by Timed Up \& Go (TUG), as well as akinesia, tremor, and memory/executive function tasks, and will reduce motor and non-motor fluctuations within the acute period of keto-induction and early ketogenic timepoints due to improved mitochondrial function and neurotransmitter signaling.

Objectives:

The primary objective is to test the hypothesis that nutritional ketosis (NK) supplemented by MCT oil in a PD cohort (MCT-KD) is feasible for a duration of three weeks. The secondary objective is to show that NK improves PD symptomatology in cognition (improved attention, recall, and executive function), mobility (TUG), and motor function (bradykinesia, akinesia and tremor) within three weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Ketogenic Diet

Group Type EXPERIMENTAL

Liquigen MCT oil

Intervention Type DIETARY_SUPPLEMENT

MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values

Arm B

Standard American Diet

Group Type ACTIVE_COMPARATOR

Standard American Diet

Intervention Type OTHER

Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liquigen MCT oil

MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values

Intervention Type DIETARY_SUPPLEMENT

Standard American Diet

Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Must be able to speak English
2. Able and willing to provide informed consent
3. Male or female older than age 50 years
4. Clinically probable diagnosis of Parkinson s Disease by UK Brain Bank Criteria, of moderate severity, with ability to safely walk independently for at least a short distance (20 feet) as determined on screening visit
5. BMI \> 18.5, to minimize potential risk from expected mild weight loss from ketogenic diet
6. eGFR \> 60 by MDRD equation (established on screening visit serum chemistry)
7. MOCA \> 20, as well as having in the investigators' assessment the ability and willingness to adhere to either of the study diets
8. Agreement to adhere to Lifestyle Considerations throughout study duration
9. Adhering to Usual Diet (SAD) at baseline, as per investigator determination

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Atypical Parkinsonism or symptoms suggestive of a diagnosis other than PD by clinical criteria
2. Family history of early onset PD (\<age 40) or known personal genetically causal etiology of PD (e.g. SNCA duplication, Parkin, PINK, DJ1) by previously obtained genetic testing
3. Currently pregnant
4. Sarcopenia defined as low BMI (\<22 Bahat et al, 2019) with clinically defined weakness
5. Medical history of cardiac arrhythmia, heart failure, stroke / cerebral hemorrhage, epilepsy, other disease of the central nervous system, active cancer, end-stage liver disease, advanced kidney disease (CKD stage 3 or ESRD), beta thalassemia, or any other medical condition deemed by the PI to pose an increased risk for taking part in the study.
6. Inherited or other metabolic disease known to be worsened by ketogenic diet, e.g. inherited defect of lipid or amino acid metabolism
7. Diabetes on SGLT2 inhibitor or uncontrolled diabetes, defined as Hemoglobin A1c \> 8.0% on screening test
8. History of kidney stones or gallbladder surgery
9. Biliary / liver disease, defined on screening labs, by presence of any of the following: Total bilirubin (TB) \> 2x ULN or \> 2 mg/dL; AST \>3x ULN; or ALT \>5x ULN
10. Uncontrolled hypertension, defined as SBP \> 180 mmHg or DBP \> 105 mmHg on screening visit
11. Hyperlipidemia defined by LDL \>/= 160 mg/dL as per ATP-III guidelines
12. Medical / psychiatric condition identified via clinical assessment in screening visit felt to impede completion of the study\*
13. Presence of PD Psychosis or dementia, or other neuropsychiatric or psychiatric illness impeding consent and fidelity to the study intervention and/or measurements
14. Dietary or allergy restrictions as determined by research team to be prohibitive for the study
15. Inability to communicate and provide informed consent in English
16. No history of previous use of ketogenic or similar diet to a degree that could interfere with study blinding

* A thorough medical and social history will be performed during the screening visit including questions regarding alcohol and substance abuse. If active alcohol abuse or other current substance abuse is identified which could increase the risk of study participation, then participants will be excluded.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No